Developer docs
API playgroundTry for free, no card

Search company profiles

Medomie

Full company profile

uuid02lu5sv

Namestring
Medomie
Legal namestring
Medomie
Websiteurl
medomie.co.il
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to commercialize Verrica Pharmaceuticals' YCANTH (VP-102) topical treatment for molluscum contagiosum within the Israeli market. Under the distribution agreement announced in July 2026, Verrica manufactures and supplies the product while Medomie is responsible for pursuing local regulatory approval and distributing YCANTH in Israel. The agreement entitles Verrica to 60% of net sales and grants Medomie eligibility for combined milestone payments of up to $8.2 million, alongside the remaining 40% net sales share.

The company's operating model is structured as a single-product, single-geography distribution entity with 1-10 employees. Its core function is regulatory navigation and channel access for a single approved dermatology therapeutic in Israel, rather than drug discovery or manufacturing. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel, bounding Medomie's addressable market to the Israeli patient population for molluscum contagiosum.

Medomie's go-to-market is exclusively through its partnership channel with Verrica; there is no evidence of additional in-house sales infrastructure beyond what is needed to execute this single distribution mandate. Revenue, once generated, derives from 40% of YCANTH net sales in Israel plus contingent milestone payments, contingent on Israeli regulatory approval being secured. The company has no publicly disclosed funding rounds, ownership structure, or management team in the available sources.

Short descriptiontext

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to seek regulatory approval for and distribute Verrica Pharmaceuticals' YCANTH (VP-102) treatment for molluscum contagiosum in the Israeli market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Keyword5 values
pharmaceutical distribution, dermatology therapeutics, molluscum treatment, specialty pharma distribution, regulatory affairs services
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Distribution
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Distribution of YCANTH
TypeTransaction Fee
Description

Medomie distributes YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie's revenue comes from the remaining 40% of net sales plus potential milestone payments.

stocktitan.net
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Supply Chain, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Medomie is an Israeli pharmaceutical distribution company that holds exclusive rights from Verrica Pharmaceuticals to seek regulatory approval and distribute YCANTH (VP-102), a topical treatment for molluscum contagiosum, in the Israeli market. The company handles local regulatory filings and commercialization while Verrica manufactures and supplies the product under a revenue-share arrangement.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Medomie Pharma is a pharmaceutical distribution company focused on bringing dermatological therapeutics to the Israeli market. The company operates as a single-product distribution entity, holding exclusive rights to distribute Verrica Pharmaceuticals' YCANTH (VP-102) for molluscum contagiosum in Israel. Under the distribution agreement, Verrica manufactures and supplies the product while Medomie handles regulatory approval and commercialization locally, with Verrica receiving 60% of net sales and up to $8.2 million in milestone payments.

Product and service1 record
1YCANTH (VP-102)
CategoryDistributed Pharmaceutical Product / Dermatology
Description

YCANTH (VP-102) is a topical treatment for molluscum contagiosum. Medomie Pharma holds exclusive distribution rights for the Israeli market, where it seeks regulatory approval and distributes the product, with Verrica manufacturing and supplying the treatment.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-07-21
Description

Medomie Pharma entered an exclusive distribution agreement with Verrica Pharmaceuticals granting Medomie rights to seek regulatory approval and distribute YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie is eligible to receive up to $8.2 million in combined regulatory and commercial milestones. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Israeli specialty biopharmaceutical company that in-licenses and commercializes therapeutics, with a strong focus on distribution partnerships and out-licensing. Comparable to Medomie in its in-licensing/distribution business model targeting international pharma assets.

TypeDirect peer
Description

Israeli clinical-stage dermatology-focused pharmaceutical company developing topical treatments. Comparable to Medomie in its Israeli base and dermatology therapeutic focus, with overlapping physician and channel relationships.

TypeEmerging player
Description

Israeli-founded dermatology-focused pharmaceutical company developing topical therapeutics. Comparable to Medomie in its dermatology focus and Israeli origin, with overlapping physician targets in the local dermatology community.

TypeBroad incumbent
Description

Israeli-founded multinational generic and specialty pharmaceutical manufacturer with established Israeli distribution operations. Comparable as a large incumbent Israeli pharma player that distributes therapeutics through local channels.

TypeEmerging player
Description

Israeli clinical-stage biopharmaceutical company that in-licenses and develops therapeutic candidates, often partnering with larger pharma for commercialization. Comparable in its Israeli base and in-licensing/partnership-driven business model.

TypeDirect peer
Description

Israeli specialty pharmaceutical company that licenses, develops, and distributes therapeutics in the Israeli market. Comparable to Medomie as a domestically focused Israeli pharma commercialization/distribution entity serving as a local partner for foreign innovators.

TypeEmerging player
Description

Israeli clinical-stage specialty pharmaceutical company developing innovative therapeutics with commercialization intended in part through distribution partnerships. Comparable to Medomie as a small Israeli specialty pharma with partnership-driven commercialization.

TypeDirect peer
Description

Israeli specialty pharmaceutical company that develops, manufactures, and commercializes specialty therapeutics, with significant distribution and licensing activities in Israel. Comparable in its Israeli specialty pharma distribution and in-licensing model.

TypeBroad incumbent
Description

Global pharmaceutical company headquartered in Israel with broad specialty, generic, and distribution operations. Comparable as the dominant Israeli pharma incumbent against which smaller specialty distributors like Medomie compete for channel and physician access.

TypeBroad incumbent
Description

Global consumer healthcare and specialty pharmaceutical company with established operations and distribution in Israel. Comparable as a larger incumbent with Israeli distribution presence in dermatology-adjacent therapeutic categories.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medomie

Pharmaceutical Distributionmedomie.co.il

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to seek regulatory approval for and distribute Verrica Pharmaceuticals' YCANTH (VP-102) treatment for molluscum contagiosum in the Israeli market.

What Medomie does

Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to commercialize Verrica Pharmaceuticals' YCANTH (VP-102) topical treatment for molluscum contagiosum within the Israeli market. Under the distribution agreement announced in July 2026, Verrica manufactures and supplies the product while Medomie is responsible for pursuing local regulatory approval and distributing YCANTH in Israel. The agreement entitles Verrica to 60% of net sales and grants Medomie eligibility for combined milestone payments of up to $8.2 million, alongside the remaining 40% net sales share.

The company's operating model is structured as a single-product, single-geography distribution entity with 1-10 employees. Its core function is regulatory navigation and channel access for a single approved dermatology therapeutic in Israel, rather than drug discovery or manufacturing. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel, bounding Medomie's addressable market to the Israeli patient population for molluscum contagiosum.

Medomie's go-to-market is exclusively through its partnership channel with Verrica; there is no evidence of additional in-house sales infrastructure beyond what is needed to execute this single distribution mandate. Revenue, once generated, derives from 40% of YCANTH net sales in Israel plus contingent milestone payments, contingent on Israeli regulatory approval being secured. The company has no publicly disclosed funding rounds, ownership structure, or management team in the available sources.

Medomie firmographics

Firmographics
Name
Medomie
Legal name
Medomie
Website
https://medomie.co.il
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Medomie is an Israel-based pharmaceutical distribution company that holds exclusive rights to seek regulatory approval for and distribute Verrica Pharmaceuticals' YCANTH (VP-102) treatment for molluscum contagiosum in the Israeli market.
Ownership category
akta.pro rank

Medomie business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Distribution of YCANTH: Medomie distributes YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie's revenue comes from the remaining 40% of net sales plus potential milestone payments.

Go-to-market motion1 record

Distribution channels1 record

Medomie product offering

Product offering

Core offering

Medomie is an Israeli pharmaceutical distribution company that holds exclusive rights from Verrica Pharmaceuticals to seek regulatory approval and distribute YCANTH (VP-102), a topical treatment for molluscum contagiosum, in the Israeli market. The company handles local regulatory filings and commercialization while Verrica manufactures and supplies the product under a revenue-share arrangement.

Product overview

Medomie Pharma is a pharmaceutical distribution company focused on bringing dermatological therapeutics to the Israeli market. The company operates as a single-product distribution entity, holding exclusive rights to distribute Verrica Pharmaceuticals' YCANTH (VP-102) for molluscum contagiosum in Israel. Under the distribution agreement, Verrica manufactures and supplies the product while Medomie handles regulatory approval and commercialization locally, with Verrica receiving 60% of net sales and up to $8.2 million in milestone payments.

Differentiator

Problem solved

Functional benefit

Products and services

  • YCANTH (VP-102) YCANTH (VP-102) is a topical treatment for molluscum contagiosum. Medomie Pharma holds exclusive distribution rights for the Israeli market, where it seeks regulatory approval and distributes the product, with Verrica manufacturing and supplying the treatment.

Companies that use Medomie

Customer profile

Segments1 record

Ideal customer profiles1 record

Medomie technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medomie partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Verrica PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 21 July 2026Medomie Pharma entered an exclusive distribution agreement with Verrica Pharmaceuticals granting Medomie rights to seek regulatory approval and distribute YCANTH for molluscum contagiosum in Israel. Verrica manufactures and supplies the product, receiving 60% of net sales. Medomie is eligible to receive up to $8.2 million in combined regulatory and commercial milestones. Verrica retains exclusive global rights to YCANTH outside of Japan and Israel.

Scale indicators2 records

Recent moves1 record

Expansion highlights3 records

Medomie competitors and assessment

Company assessment

Direct peers

  • RedHill Biopharma: Israeli specialty biopharmaceutical company that in-licenses and commercializes therapeutics, with a strong focus on distribution partnerships and out-licensing. Comparable to Medomie in its in-licensing/distribution business model targeting international pharma assets.
  • Sol-Gel Technologies: Israeli clinical-stage dermatology-focused pharmaceutical company developing topical treatments. Comparable to Medomie in its Israeli base and dermatology therapeutic focus, with overlapping physician and channel relationships.
  • Dexcel Pharma: Israeli specialty pharmaceutical company that licenses, develops, and distributes therapeutics in the Israeli market. Comparable to Medomie as a domestically focused Israeli pharma commercialization/distribution entity serving as a local partner for foreign innovators.
  • Kamada Ltd. Israeli specialty pharmaceutical company that develops, manufactures, and commercializes specialty therapeutics, with significant distribution and licensing activities in Israel. Comparable in its Israeli specialty pharma distribution and in-licensing model.

Emerging players

  • Vyne Therapeutics: Israeli-founded dermatology-focused pharmaceutical company developing topical therapeutics. Comparable to Medomie in its dermatology focus and Israeli origin, with overlapping physician targets in the local dermatology community.
  • BioLineRx: Israeli clinical-stage biopharmaceutical company that in-licenses and develops therapeutic candidates, often partnering with larger pharma for commercialization. Comparable in its Israeli base and in-licensing/partnership-driven business model.
  • PolyPid Ltd. Israeli clinical-stage specialty pharmaceutical company developing innovative therapeutics with commercialization intended in part through distribution partnerships. Comparable to Medomie as a small Israeli specialty pharma with partnership-driven commercialization.

Broad incumbents

  • Taro Pharmaceutical Industries: Israeli-founded multinational generic and specialty pharmaceutical manufacturer with established Israeli distribution operations. Comparable as a large incumbent Israeli pharma player that distributes therapeutics through local channels.
  • Teva Pharmaceutical Industries: Global pharmaceutical company headquartered in Israel with broad specialty, generic, and distribution operations. Comparable as the dominant Israeli pharma incumbent against which smaller specialty distributors like Medomie compete for channel and physician access.
  • Perrigo Company: Global consumer healthcare and specialty pharmaceutical company with established operations and distribution in Israel. Comparable as a larger incumbent with Israeli distribution presence in dermatology-adjacent therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Medomie social profiles

Digital presence

Medomie financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medomie leadership team

Management profile

Number of profiles

Medomie funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medomie M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medomie

What does Medomie do?

Medomie is an Israeli pharmaceutical distribution company that holds exclusive rights from Verrica Pharmaceuticals to seek regulatory approval and distribute YCANTH (VP-102), a topical treatment for molluscum contagiosum, in the Israeli market. The company handles local regulatory filings and commercialization while Verrica manufactures and supplies the product under a revenue-share arrangement.

Is Medomie a public or private company?

Medomie is a private company. It is classified as unknown and is currently operating.

When was Medomie founded?

Medomie was founded in -1. It employs 11 to 50 people.

How does Medomie make money?

One revenue line is on record: distribution of YCANTH.

Who are Medomie's main competitors?

Direct peers on record are RedHill Biopharma, Sol-Gel Technologies, Dexcel Pharma and Kamada Ltd.. Emerging players are Vyne Therapeutics, BioLineRx and PolyPid Ltd.. Broad incumbents are Taro Pharmaceutical Industries, Teva Pharmaceutical Industries and Perrigo Company.

Does Medomie have an API?

No public API is recorded for Medomie.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals